IL6 and familial pancreatic carcinoma: To understand whether LIF and IL-6 have different effects on the activation of YAP/TAZ-TEAD in pancreatic cancers, we treated serum-starved human pancreatic cancer cells with IL-6 or LIF at 100 ng/mL.